Core Viewpoint - The Hong Kong stock market currently has over 100 companies queued for IPOs, raising concerns about a potential "backlog" and the adequacy of the Hong Kong Stock Exchange's (HKEX) review staff [1] Group 1: Market Conditions - There are 376 IPOs currently awaiting hearing on the HKEX, indicating a significant demand for listings [1] - HKEX Chairman, Tang Ka Sing, emphasized that while market liquidity and trading volume are important, the quality of the market is paramount for attracting capital, investors, and companies [1] Group 2: Regulatory Insights - HKEX CEO, Chan Yi Ting, referred to a recent circular from the Securities and Futures Commission (SFC) as a "friendly reminder," highlighting the focus on the quality of materials submitted by sponsors rather than the quality of the listing applicants themselves [1] - The SFC's increased scrutiny on sponsor submissions aims to maintain the high quality of listed companies, which is a key factor in attracting global investors to Hong Kong [1]

Group 1 - The Hong Kong IPO market has shown strong momentum since 2026, with the number of IPO applications increasing from over 300 at the end of 2025 to 414 by the end of January 2026, indicating a rapid growth of nearly 100 applications in just one month [2] - Hong Kong Exchanges and Clearing Limited (HKEX) has regained the top position globally in IPO financing in 2025, attracting three of the top five global IPOs, with average daily trading volume doubling to approximately 250 billion HKD [3] - The current market supply is active, with many companies eager to list in Hong Kong, and the demand side remains strong, suggesting that high-quality IPOs will continue to attract international capital [4] Group 2 - HKEX has received over 400 IPO applications, including 11 from international companies outside mainland China, demonstrating that global quality enterprises are keen to enter the Chinese market through Hong Kong [3][4] - The quality of IPOs is emphasized as a key factor for attracting global investors, with HKEX and the Hong Kong Securities and Futures Commission (SFC) committed to maintaining high standards in the IPO approval process [3][4] - There is a noticeable trend of foreign capital returning to the Hong Kong market since 2025, driven by a desire for diversified asset allocation amid rising geopolitical uncertainties [5] Group 3 - HKEX plans to enhance its fixed income market as a core strategic focus for 2026, aiming to provide a comprehensive asset allocation solution beyond just equities [6] - The exchange has invested in the Central Moneymarkets Unit (CMU) to build a foundation for the fixed income market, with plans to expand offerings in bond issuance and repurchase transactions [6] - HKEX intends to collaborate with the Hong Kong Monetary Authority, SFC, and mainland partners to develop a robust ecosystem for fixed income markets and expand into commodities [6]

Core Viewpoint - The Hong Kong IPO market is experiencing a significant surge in new listings, with over 400 applications received by January 2026, indicating strong demand and capacity to absorb new supply without concerns of a "backlog" [5][10]. Group 1: Market Performance - Since 2025, the Hong Kong capital market has shown robust momentum, with the number of IPO applications increasing from over 300 at the end of 2025 to 414 by the end of January 2026, marking a rapid growth of nearly 100 applications in just one month [5]. - The Hong Kong Stock Exchange (HKEX) reclaimed the top position globally in IPO financing in 2025, attracting three of the top five global IPOs, with daily trading volume doubling to approximately 250 billion HKD [7]. - As of early 2026, the average daily trading volume reached 278 billion HKD, reflecting continued strong market activity [7]. Group 2: Quality of IPOs - The quality of IPOs is emphasized as a critical factor for the success of the Hong Kong market, with the HKEX and the Hong Kong Securities and Futures Commission (SFC) focusing on the quality of listing documents submitted by sponsors [8]. - A joint statement from the HKEX and SFC in November 2024 committed to a 40-working-day timeline for IPO approvals, contingent on the quality of submitted materials [8]. Group 3: Foreign Investment Interest - There has been a noticeable return of foreign capital to the Hong Kong market since 2025, driven by a desire for diversified asset allocation amid rising geopolitical uncertainties [12]. - The HKEX is seen as providing attractive investment opportunities, with significant interest from international investors noted at recent global forums [12]. Group 4: Future Strategies - The HKEX plans to enhance its fixed income market offerings, recognizing the need for a comprehensive asset allocation strategy beyond equities [13]. - The exchange has invested in the Central Moneymarkets Unit (CMU) to build a foundation for the fixed income market and aims to collaborate with various stakeholders to develop a robust market ecosystem [13].

Core Viewpoint - The Hong Kong capital market has shown strong momentum since 2026, with a significant increase in IPO applications, raising concerns about the market's capacity to absorb this influx [1][5]. Group 1: IPO Market Performance - The number of IPO applications in Hong Kong surged from over 300 at the end of 2025 to 414 by the end of January 2026, indicating a rapid growth of nearly 100 applications in just one month [1]. - Hong Kong Exchanges and Clearing Limited (HKEX) regained the top position globally in IPO financing in 2025, with a daily trading volume that doubled to approximately 250 billion HKD, and the average daily trading volume for 2026 has reached 278 billion HKD [3]. - The market has received over 400 IPO applications, including 11 from international companies outside mainland China, showcasing global interest in entering the Chinese market through Hong Kong [3]. Group 2: Quality of IPOs - The quality of IPOs is emphasized as a key factor for attracting global investors, with the HKEX and the Hong Kong Securities and Futures Commission (SFC) focusing on the quality of sponsor submissions rather than the qualifications of the applicants themselves [3][5]. - HKEX has committed to a 40-working-day timeline for IPO approvals, contingent on the quality of submitted materials, which is aimed at ensuring high-quality listings [3]. Group 3: Market Capacity and Demand - HKEX's CEO expressed confidence that the market can absorb the influx of IPOs, attributing this to strong demand from international capital seeking diversified investment opportunities [5]. - The CEO highlighted that as long as the IPOs are of high quality, foreign capital will continue to flow into the market, negating concerns about a "backlog" of IPOs [5]. Group 4: Global Investor Interest - Since 2025, there has been a noticeable return of foreign capital to the Hong Kong market, driven by a desire for diversified asset allocation amid rising geopolitical uncertainties [7]. - The CEO noted that the Hong Kong market is providing attractive investment opportunities, which has been confirmed by international interest observed at events like the World Economic Forum in Davos [7]. Group 5: Future Market Development - HKEX plans to enhance its fixed income market as a core strategic focus for 2026, aiming to provide a broader range of investment options beyond equities [8]. - The exchange has invested in the Central Moneymarkets Unit (CMU) to build a foundation for the fixed income market and intends to collaborate with regulatory bodies and partners to develop a comprehensive market ecosystem [8].

Core Viewpoint - The Hong Kong financial market is experiencing a surge in IPO applications, raising concerns about potential tightening of approval processes and the risk of an "IPO backlog" [1][2]. Group 1: IPO Market Dynamics - The Hong Kong Stock Exchange (HKEX) President, Charles Li, stated that as long as there is sufficient demand, the market can absorb all high-quality listings [1]. - Recent communications from the Hong Kong Securities and Futures Commission (SFC) to 13 sponsors aim to enhance the quality of IPO application materials rather than targeting the companies themselves [2]. - The HKEX has committed to maintaining an IPO review cycle of 40 working days, contingent on the submission of high-quality and complete application materials [3]. Group 2: Market Confidence and Quality - Concerns about an "IPO backlog" are unfounded, as the Hong Kong market benefits from free capital flow and the ability to attract global investment through quality IPOs [3][4]. - There is a strong demand from international investors for quality assets, particularly as they seek diversification outside the U.S. market [4]. - Among the over 400 IPO applications, 11 are from international companies, indicating a broad geographical interest in the Hong Kong market [4]. Group 3: Fixed Income Market Strategy - The HKEX is focusing on expanding its fixed income market, which is seen as a critical area for strategic growth [5][6]. - The exchange has invested in the Central Moneymarkets Unit (CMU) to build a foundation for the fixed income market, aiming to create a comprehensive ecosystem for bond issuance and trading [6]. - The development of the fixed income market is viewed as a long-term project that requires collaboration with regulatory bodies and mainland partners [7].

Core Viewpoint - The Hong Kong stock market's 18A IPO sector has experienced a dramatic reversal, with 80% of biotech companies failing to secure listings in the second half of the year after a frenzied first half [1][3]. Group 1: IPO Market Dynamics - In 2025, nearly 70 companies applied for 18A IPOs, but only about 15 are expected to succeed, indicating that 4 out of 5 companies will be eliminated [3]. - The biotech sector has seen a significant downturn, with many companies experiencing drastic stock price declines, some losing half their value in a short period [3][9]. - The backlog of IPO applications has created a bottleneck, leading to increased scrutiny and higher entry barriers for companies seeking to go public [5]. Group 2: Investment and Market Sentiment - The initial excitement for IPOs was sparked by the successful debut of InnoCare Pharma in April 2025, which saw a 116% surge on its first day, raising HKD 15.55 billion [7]. - Major biotech firms like Sihuan Pharmaceutical and Jiangsu Hengrui Medicine have seen their market valuations soar, but this is juxtaposed with the underlying struggles of the biotech sector [9]. - The past two years have seen a significant decline in the primary market, with only 325 financing events totaling HKD 41.4 billion in the first three quarters of 2025, compared to 992 events totaling HKD 207.1 billion in 2021 [11]. Group 3: Strategic Recommendations for Biotech Companies - Companies should avoid relying on IPOs as a lifeline and instead focus on eliminating non-core projects to concentrate resources on late-stage pipelines, which have a higher likelihood of successful listings [15][16]. - Collaborations with multinational and large pharmaceutical companies are encouraged to secure funding and leverage their research and distribution resources [18]. - The industry must return to rationality, recognizing that drug development is a slow process and that companies should not be swayed by short-term market sentiments [20].